Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation

Rosaria Calia, C Lai, P Aceto, M Luciani, Jacopo Romagnoli, S Lai, A Gargiulo, Franco Citterio

Research output: Contribution to journalArticle

Abstract

This study investigated whether switching from the twice-daily (Prograf; TAC) to the once-daily formulation of tacrolimus with extended release (Advagraf; XL) affected quality of life, anxiety, and transplant benefit perception after allogeneic kidney transplantation.
Original languageEnglish
Pages (from-to)1020-1023
Number of pages4
JournalTransplantation Proceedings
Volume43
DOIs
Publication statusPublished - 2011

Keywords

  • Adult
  • Aged
  • Analysis of Variance
  • Anxiety
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Drug Monitoring
  • Female
  • Graft Rejection
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Immunosuppressive Agents
  • Italy
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Perception
  • Psychiatric Status Rating Scales
  • Quality of Life
  • Questionnaires
  • Tacrolimus
  • Time Factors
  • Treatment Outcome
  • Truth Disclosure

Fingerprint

Dive into the research topics of 'Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation'. Together they form a unique fingerprint.

Cite this